Navigation Links
ACEA Biosciences and PhysioStim Announce Partnership to Provide Comprehensive In Vitro Cardiac Safety Assessment Services

ACEA Biosciences Inc. (ACEA), now a part of Agilent Technologies, is a pioneer in the development and commercialization of high performance, cutting-edge cell analysis platforms for life science research. Today, ACEA Biosciences and PhysioStim, a leading European CRO with GLP-certified expertise in cardiovascular pharmacology and electrophysiology, are announcing a partnership to provide comprehensive in vitro cardiac safety and toxicity assessment services for pharmaceutical and biotechnology companies in Europe.

Cardiac liability of pharmaceutical compounds is a pervasive issue in drug development that needs to be carefully managed and mitigated. PhysioStim will adopt and incorporate ACEA’s xCELLigence RTCA CardioECR system as an important part of its service offerings together with human induced pluripotent stem cells (hi-PSCs), to assess the cardiac liability of pharmaceutical compounds and biologics on cardiomyocyte contractility, integrated ion-channel activity and longer-term viability, and structural toxicity.

PhysioStim is one of Europe’s most recognized and reliable CROs offering electrophysiological studies, preclinical resources, and dedicated expertise in evaluating compounds under GLP (Good Laboratory Practices), in accordance with the International Conference of Harmonization (ICH) S7A and S7B guidelines for cardiac safety assessment. More recently, PhysioStim has taken steps to be aligned with the upcoming FDA sponsored Comprehensive In Vitro Pro-Arrhythmia (CiPA) initiative guidelines. As part of this initiative, compounds are ranked for their pro-arrhythmic liability using a suite of approaches including the screening of compounds against critical cardiac ion channels expressed recombinantly in non-cardiac cell lines, using in silico methodology and utilizing human-derived cardiomyocytes, such as hiPSCs.

ACEA is the developer of xCELLigence RTCA products with greater than 3000 installations spanning academia, industry and government laboratories. The xCELLigence CardioECR system combines high- frequency measurement of cellular impedance with multielectrode array technology to simultaneously assess cardiomyocyte contractility, viability, and electrophysiology. The system has distinctive features such as enhanced impedance data acquisition rate (everyone millisecond), simultaneous recording of contractility and electrophysiology and electrical pacing feature all in a microtiter plate format which makes it amenable and attractive for the screening of compounds which may have cardiac liability. The CardioECR system was one of the few selected technologies which were utilized in the validation of compounds as part of the CiPA initiative.

“We are continuing to build our service capabilities with more predictive assays for assessment of cardiac liability, and incorporation ACEA’s CardioECR system is an example of how we are aligning ourselves for the future with the CiPA guidelines,” stated Dr. Marie Le Grand, CEO of PhysioStim. “The fact that the CardioECR system is not only able to assess integrated ion channel activity in hiPSCs, but also contractility and viability is an added advantage which will allow us to screen compounds for cardiac liability with more confidence.”

As part of this partnership, ACEA will direct and refer all service requests in Europe on the CardioECR system to PhysioStim.

“We are happy to work with world-class electrophysiologists and scientists at PhysioStim to better serve our existing customers and those clients that are eager to learn more about the potential cardiac liability of their compounds,” stated Dr. Abassi, VP of Business Development at ACEA.

About PhysioStim
PhysioStim is an independent preclinical CRO with high-level expertise in the field of cardiovascular pharmacology and electrophysiology. The company was founded in 2000 by Dr. Marie Le Grand, who is the current CEO, and is located in Lautrec in Southern France. PhysioStim aims to address the growing need of the pharmaceutical industry and biotech companies to conduct high-quality preclinical assays and studies. Over the years, PhysioStim has grown into a highly-valued team that rises to the challenge of designing and conducting high-quality studies for drug development and derisking of compounds.
For more information, visit

About ACEA Biosciences, Inc.
Founded in 2002, ACEA Biosciences, Inc., now a part of Agilent Technologies, is a pioneer in the development and commercialization of high performance, cutting-edge cell analysis platforms for life science research. Researchers are advancing their studies utilizing over 3,000 placed instruments for broad and diverse applications. The technology has been cited in over 2000 peer-reviewed publications. ACEA’s xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers are used in pre-clinical drug discovery and development, toxicity, safety pharmacology, and basic academic research.

For more information, visit

Frédéric Delteil, Business Development Manager
+33 (6)

Richard Printemps, Chief Scientific Officer
+33 (5)

ACEA Biosciences
Jeff Xue, Director of Marketing

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. Murrieta Genomics and SeqOnce Biosciences Team to Simplify and Commercialize Next Generation Sequencing Sample Preparation
2. ABCT, Connecticut’s Newest Accelerator Program for Biosciences Ventures, Announces 2019 Cohort of Life Science Startups
3. Predicine and Flagship Biosciences Partner to Support Global Biomarker Development
4. Caprion Biosciences Expands Biomarker Panel Portfolio to Include Predictive Tuberculosis (TB) Infections
5. ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
6. ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T Cell Therapy
7. Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
8. Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
9. ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer
10. Pendant Biosciences Announces Acceptance into JLABS @ Toronto
11. Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World
Post Your Comments:
(Date:8/12/2020)... ... August 11, 2020 , ... ... engineering firm, is making available for free its new white paper – ... transport simulation testing into today’s biologics licensing application (BLA). In response, Modality ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – ... , Known as MediVet Biologics since its formation in 2016, ... The new Ardent Animal Health will build on its base of innovative therapies for ...
(Date:7/31/2020)... ... 2020 , ... Anomet Products has introduced new custom composite ... with CRM, neurostimulation, vascular, and related devices. , Anomet Medical Clad Wire ... and cost criteria; especially where solid wire is limited. Typical configurations for implantable ...
(Date:7/31/2020)... (PRWEB) , ... July 30, ... ... of cloud-based software for the life sciences industry, today announced the release ... platform designed specifically for Medical Science Liaisons (MSLs) and other field medical ...
Breaking Biology Technology:
(Date:8/26/2020)... ... August 25, 2020 , ... ... developing novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical ... pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution in patients ...
(Date:8/26/2020)... ... ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, is ... is the most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions made ... three-year revenue growth of 71 percent. , The Inc. 5000 list represents a ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, ... that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational ... the treatment of severe COVID-19. Approval of this IND allows Sentien to initiate ...
Breaking Biology News(10 mins):